Baricitinib pediatric indications — approvals and clinical development for juvenile idiopathic arthritis, pediatric atopic dermatitis, and pediatric alopecia areata — represent the systematic expansion of baricitinib's indication portfolio into younger patient populations, with the Baricitinib Market reflecting pediatric approval as a market expansion strategy alongside adult...

The therapeutic footprint of Janus kinase inhibitors is widening as we move through 2026. In the Baricitinib Market the focus has shifted from managing traditional autoimmune conditions to capturing new, high-demand dermatological sectors. While originally established as a powerful treatment for rheumatoid arthritis, baricitinib is now seeing a massive surge in adoption for severe alopecia...